BCM
NTLA icon

Burrage Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Burrage Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-630
Closed -$46K – 25
2021
Q1 		$46K Buy
+630
New +$42.3K 0.04% 27

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Burrage Capital Management's NTLA Position: Q3 2021 in Review

Burrage Capital Management sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 63,634 shares — an estimated $10.3M sold.

Burrage Capital Management first reported a position in NTLA in Q4 2020 and held it in 3 quarters. The position peaked at $10.3M in Q2 2021. 364 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

  • Burrage Capital Management reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Burrage Capital Management sold 63,634 Intellia Therapeutics shares in Q3 2021, an estimated $10.3M.
  • Burrage Capital Management first reported a position in Intellia Therapeutics in Q4 2020 and held it in 3 quarters.
  • Burrage Capital Management's Intellia Therapeutics position peaked at $10.3M in Q2 2021.
  • 364 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Burrage Capital Management's 13F filing for Q3 2021.